Praxis Precision Medicines, Inc (PRAX)
| Market Cap | $8.53B+57.0% |
| Revenue (ttm) | n/a |
| Net Income | -$359.43M |
| EPS | -$12.82 |
| Shares Out | 27.95M |
| PE Ratio | n/a |
| Forward PE | -31.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 836,922 |
| Open | $315.74 |
| Previous Close | $310.27 |
| Day's Range | $300.99 - $319.00 |
| 52-Week Range | $160.11 - $392.70 |
| Beta | 2.84 |
| Analysts | Strong Buy |
| Price Target | $674.48(+121.10%) |
| Earnings Date | Nov 9, 2026 |
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PRAX stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of PRAX by members of U.S. Congress
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Sep 29, 2026 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Jul 30, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Jul 30, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Jul 29, 2026 |
Recently reported changes in PRAX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PRAX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PRAX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PRAX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PRAX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from PRAX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple analyst upgrades and price target increases alongside FDA milestone announcements for lead drug candidates create solidly bullish coverage.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| IBRN | iShares Neuroscience and Healthcare ETF | 4.30% |
| GNOM | Global X - Genomics & Biotechnology ETF | 3.03% |
| TDNA | T. Rowe Price Biotech ETF | 2.26% |
| LFSC | F/M Emerald Life Sciences Innovation ETF | 2.23% |
| XBI | State Street SPDR S&P Biotech ETF | 1.41% |
| GURU | Global X - Guru Index ETF | 1.28% |
| HELX | Franklin Genomic Advancements ETF | 1.18% |
| PCSG | Polen 5Perspectives Small-Mid Growth ETF | 1.15% |
| WDNA | WisdomTree BioRevolution Fund | 1.05% |
| MMSC | First Trust Multi-Manager Small Cap Opportunities ETF | 1.02% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.96% |
| MEDI | Harbor Health Care ETF (MEDI) | 0.93% |
Weight is the stock’s share of each fund’s holdings.
